Robert F. McCullough
Keine laufenden Positionen mehr
Profil
Robert F.
McCullough worked as Chairman, Chief Executive & Financial Officer at CytoCore, Inc. from 2010 to 2014.
He was also President & Portfolio Manager at Summitcrest Capital, Inc. from 2003 to 2011 and Portfolio Manager at Presidio Management from 1999 to 2003.
Ehemalige bekannte Positionen von Robert F. McCullough
| Unternehmen | Position | Ende |
|---|---|---|
Summitcrest Capital, Inc.
 Summitcrest Capital, Inc. Investment ManagersFinance Summitcrest Capital, Inc. provides investment advisory services. | Präsident | - |
| Presidio Management | Corporate Officer/Principal | 01.07.2003 |
CytoCore, Inc.
 CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL. | Vorstandsvorsitzender | 03.04.2014 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
CytoCore, Inc.
CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL. | Health Technology |
Summitcrest Capital, Inc.
Summitcrest Capital, Inc. Investment ManagersFinance Summitcrest Capital, Inc. provides investment advisory services. | Finance |
| Presidio Management |
